FDA Approves LOQTORZI in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
Scheduling Order Issued in REGENXBIO v. Sarepta Litigation
Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patent
FDA Accepts BLA for Dr. Reddy’s Rituximab Biosimilar for Review
EMA Accepts MAA for Dong-A ST’s Ustekinumab Biosimilar
USPTO Extends Deadline for Comments on USPTO-FDA Collaboration Initiatives
Alvotech and Bioventure Announce Approval of ADALIMUMAB Biosimilar in Saudi Arabia
International Biosimilar Market Updates
Organon Launches HERCEPTIN and AVASTIN Biosimilars in Canada
Subscribe: Subscribe via RSS
Blogs
Firm/Org